Background: Representatives from 8 global cancer coalitions/alliances, representing 650 cancer patient groups and the interests of over 14 million patients have come together during the pandemic to review and evaluate the patient-perspective impact. Cancer services have faced challenges as a result of COVID-19, including suspension of screening and diagnostic services; delays in diagnosis leading to higher mortality rates; cancellation/deferral of life-saving treatments; changes in treatment regimens and suspension of vital research. For organisations that provide support to cancer patients, declining income, the need to reduce staff and move to virtual working practices has put extra strain while demand for support due to the pandemic has increased.Methods: 5 coalitions surveyed their member organisations. A number of coalitions consulted their members by individual surveys or consultations.
11074 Background: Treatment options for patients (pts) with colorectal cancer (CRC) have increased in the last years. However, there are no validated prospective molecular markers in CRC to select which agents are better to treat any individual case. The aim of this study was to determine the feasibility of developing an implementing a biomarker panel to guide treatment selection in this setting. Methods: Colorectal cancer tumors were prospectively analyzed with a predefined set of 11 molecular targets, including: KRas and PI3K mutations, EGFR amplification (FISH), and ERCC-1, TS, TP expression by IHC. Clinical characteristics and response to chemotherapy were registered. To establish the utility of this panel, we determine as congruent-treatment if the panel predict the best treatment in patients with more of 1 chemotherapy line and no-congruent-treatment if do not. Results: A total of 84 patients were studied. Only 6 % required a repeated biopsy to obtain sufficient tumor for marker analysis. In 81 % of patients was feasible to study almost 8/11 targets. There were 29 pts (39%) with KRas mutant CRC; 3 pts with PI3K mutations (4%, all of them with KRas mutation); and 2 patients with EGFR amplification. ERCC-1 was positive in 5/78 (6.4%) and TS was positive in 47%. None of 54 pts had TP positivity. Clinical floow up was available in 66 pts (44 males, median age 59, 93% ECOG 0–1). Nineteen patients had early CRC; 23 with metastatic CRC treated with a first line chemotherapy and 24 with advanced CRC treated with 2 or more prior regimens. In this last group for whom the response to multiple agents is known, the panel predictive the most effective treatment in 14 of 24 cases. Conclusions: This targeted-therapy-panel is feasible to implement and should be explore to predict treatment response to CRC . No significant financial relationships to disclose.
receive NAC. Sites of recurrence were classified as urothelial (urethra, upper tract), pelvic, abdominal, thoracic, and other (soft tissue, bone, brain).RESULTS: A total of 1456 patients underwent RC for M0 MIBC during the time period of study, of whom 101 (6.94%) received NAC. Clinicopathologic characteristics are provided in the Table . Notably, patients treated with NAC were more likely to have higher pT stage (62.4% pT3/pT4 disease vs 46.6%; p ¼ 0.007) and positive soft tissue margins (4.0% vs 1.4%; p ¼ 0.05). Median follow-up after surgery was 9.5 years (IQR 5.4,15.6), during which time 614 patients experienced recurrence (64 in the NAC+RC cohort, 550 in the RC-alone group). Among patients who recurred, the median time to recurrence after NAC+RC was 5.6 months (IQR 3.1, 15.6), versus 10.7 months (IQR 5.5, 22.8) after RC alone (p ¼ 0.04). Patients with recurrence after NAC were equally likely to be diagnosed with multiple sites of metastases versus RC-only patients (60.9% versus 53.5%; p ¼ 0.50). Moreover, the location of initial recurrence did not differ significantly between patients treated with NAC+RC versus RC alone (summarized in Table ).CONCLUSIONS: Receipt of NAC does not appear to alter sitespecific patterns of recurrence among patients who experience relapse after RC. These data suggest that the NAC may not alter the biologic pathways of dissemination, and that similar postoperative oncologic surveillance may be applied after RC regardless of patients' prior receipt of NAC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.